RecruitingRecruiting
Daily Aspirin Treatment After Preeclampsia
NCT06168461 · University of Iowa
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Aspirin for the Treatment of Vascular Dysfunction After Preeclampsia
About this study
Women who develop preeclampsia during pregnancy are four times more likely to develop cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs may be related to lasting blood vessel damage after the pregnancy but there are currently no specific treatment strategies to prevent this disease progression. This study addresses this public health issue by examining whether starting low dose aspirin therapy after pregnancy is an effective treatment for lasting blood vessel damage in order to inform better clinical management of cardiovascular disease risk in women who have had preeclampsia.
Eligibility criteria
Inclusion Criteria:
* had preeclampsia in the past 5 years,
* 18 years or older
Exclusion criteria:
* current daily aspirin use,
* skin diseases,
* current tobacco or nicotine use (including vaping),
* diagnosed or suspected hepatic or metabolic disease including chronic kidney disease (CKD) defined as reduced eGFR \< 60 mL/min/1.73m2,
* statin or other cholesterol-lowering medication,
* current antihypertensive medication,
* history of hypertension prior to pregnancy,
* history of gestational diabetes,
* currently pregnancy,
* body mass index \<18.5 kg/m2,
* allergy to materials used during the experiment.(e.g. latex),
* known allergies to study drugs,
* bleeding disorders, peptic ulcer disease, gastritis, GI bleeding and gastroesophageal reflux disease (GERD).
Study design
Enrollment target: 40 participants
Allocation: randomized
Masking: quadruple
Age groups: adult
Timeline
Starts: 2023-11-01
Estimated completion: 2026-06
Last updated: 2025-12-15
Interventions
Drug: AspirinDrug: Placebo
Primary outcomes
- • magnitude of microvascular endothelial function (baseline, 12 weeks)
- • magnitude of brachial artery endothelial function (baseline, 12 weeks)
- • magnitude of microvascular endothelin-1 mediated constriction (baseline, 12 weeks)
Sponsor
Anna Stanhewicz, PhD · other
Contacts & investigators
ContactAnna Reid-Stanhewicz, PHD · contact · anna-stanhewicz@uiowa.edu · 319-467-1732
All locations (1)
University of IowaRecruiting
Iowa City, Iowa, United States